Developing natural marine products for treating liver diseases

Abstract

In recent years, marine-derived bioactive compounds have gained increasing attention because of their higher biodiversity vs land-derived compounds. A number of marine-derived compounds are proven to improve lipid metabolism, modulate the gut microbiota, and possess anti-inflammatory, antioxidant, antibacterial, antiviral, and antitumor activities. With the increasing understanding of the molecular landscape underlying the pathogenesis of chronic liver diseases, interest has spiked in developing new therapeutic drugs and medicine food homology from marine sources for the prevention and treatment of liver diseases.

Actinoquinazolinone, a New Quinazolinone Derivative from a Marine Bacterium Streptomyces sp. CNQ-617, Suppresses the Motility of Gastric Cancer Cells

“…Marine microorganisms, including actinobacteria, have emerged as a promising source for the discovery of novel bioactive compounds with potential pharmacological properties [ 8 , 9 ]. Actinobacteria are Gram-positive bacteria that have been extensively studied for their ability to produce secondary metabolites with a wide range of biological activities.…”

Editorial: Biologically active products as therapeutic options for the treatment of cardiovascular diseases related to liver injury

“…These conditions are complex problems, since heart diseases (chronic or acute heart failure) affect the liver and liver diseases affect the heart. With increasingly urbanized lifestyles and dietary changes involving high caloric contents, the overall prevalence of non-alcoholic fatty liver disease (NAFLD) has increased dramatically ( Wei and Guo, 2022 ). Beyond NAFLD, liver disease afflicts over 10% of the world population ( Mishra and Tiwari, 2011 ; Zhang et al, 2013 ), including chronic hepatitis, alcoholic steatosis, fibrosis, cirrhosis and hepatocellular carcinoma (HCC), which are the most health-threatening conditions drawing considerable attention from medical professionals and scientists.…”

“…Beyond NAFLD, liver disease afflicts over 10% of the world population ( Mishra and Tiwari, 2011 ; Zhang et al, 2013 ), including chronic hepatitis, alcoholic steatosis, fibrosis, cirrhosis and hepatocellular carcinoma (HCC), which are the most health-threatening conditions drawing considerable attention from medical professionals and scientists. NAFLD is associated with metabolic syndrome and the development of cardiovascular diseases ( Wei and Guo, 2022 ). Therefore, it is crucial to identify interactions between heart and liver, in order to provide the best treatment for both ( Correale et al, 2018 ).…”

“…Cardiac and hepatic diseases require effective and cost-efficient treatments ( Wei and Guo, 2022 ). Biological active products can protect both liver and cardiovascular system.…”